Email This

A 69-Year-Old Man with Prostate Cancer and Extensive Spontaneous Ecchymoses CME

Man-Chiu Poon, MD, MScAuthor Information and Disclosures

Release Date: July 18, 2008; Valid for credit through October 1, 2008

Credits Available

Physicians - maximum of 1.0 AMA PRA Category 1 Credit(s)™ for physicians

To participate in this internet activity: (1) review the target audience, learning objectives, and author disclosures; (2) study the educational content; (3) take the post-test and/or complete the evaluation; (4) view/print certificate View details.

Contents of This CME Activity

A 69-Year-Old Man With Prostate Cancer and Extensive Spontaneous Ecchymoses

Go to CME Test Questions

Legal Disclaimer

The materials presented here were not produced by eMedicine and do not necessarily reflect the views of eMedicine or companies that support educational programming on www.emedicine.com. These materials may discuss therapeutic products that have not been approved by the US Food and Drug Administration and off-label uses of approved products. A qualified health care professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in this educational activity.

This activity has expired.
The accredited provider can no longer issue certificates for this activity. Medscape cannot attest to the timeliness of expired CME activities.
CME Information

Learning Objectives

After successfully completing this course, participants should be able to:

List the key signs and symptoms that should prompt a workup for acquired hemophilia in elderly men,
Identify laboratory parameters that may be helpful in the diagnosis of acquired hemophilia, and
Choose a treatment plan for a patient with acquired hemophilia.

Author Disclosures

Man-Chiu Poon, MD, MSc
Disclosure: Sources of Funding for Research:
Consulting Agreements: Member of Expert Panel – Glanzmann's Thrombasthenia Registry (Novo Nordisk)
Speakers Bureau/Honorarium Agreements: none
Financial Interests/Stock Ownership: none
Discussion of Off-label, Investigational, or Experimental Drug Use: Rituximab (anti-CD20)

This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of Postgraduate Institute for Medicine (PIM) and DesignWrite. PIM is accredited by the ACCME to provide continuing medical education for physicians.

Postgraduate Institute for Medicine designates this educational activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Contact This Provider